# An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal

> **NCT02180438** · PHASE4 · COMPLETED · sponsor: **University of Washington** · enrollment: 30 (actual)

## Conditions studied

- HIV-2 Infection

## Interventions

- **DRUG:** Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks

## Key facts

- **NCT ID:** NCT02180438
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180438, "An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02180438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*